Lightnews — Scholar-powered news

Jason M. Schenkel @jmschenkel.bsky.social · Aug 25

I am grateful to have trained at such an incredible center during my graduate school years. Marc’s contributions at the helm of the CFI cannot be understated. Thank you Marc, for your service and leadership!

Reposted by Jason M. Schenkel

Center for Immunology-UMN @cfi-umn.bsky.social · Aug 25

With deep gratitude, we thank Dr. Marc Jenkins for his decades of leadership, mentorship, and dedication to the Center for Immunology. The foundation he built will guide and inspire us for years to come.

2 6 16

Jason M. Schenkel @jmschenkel.bsky.social · Jul 24

Fantastic new paper looking at the extrinsic effects of PD-1 loss! Check it out.

Journal of Experimental Medicine @jem.org · Jul 24

@kepauken.bsky.social, Markson, Sharpe et al. @harvardmed.bsky.social show that when PD-1–expressing and PD-1 knockout CD8+ T cells are within the same tumor microenvironment, both cell types exhibit similarly enhanced functions. rupress.org/jem/article/...

1 1 10

Reposted by Jason M. Schenkel

MD Anderson Cancer Center @mdanderson.bsky.social · Jul 11

Congratulations to the 2025 Sabin Family Fellowship recipients, 10 early career researchers recognized for their bold, high-impact cancer research.

Thank you to the Sabin Family Fellowship for supporting the next generation of innovators. http://spr.ly/633254IbgR #EndCancer

MD Anderson announces 10th cohort of Andrew Sabin Family Fellows

The University of Texas MD Anderson Cancer Center today announced its 10th cohort of Andrew Sabin Family Fellows, comprised of 10 early career cancer researchers. Created to provide a dedicated source of funding for emerging clinician and scientist leaders, the Sabin Family Fellowship supports groundbreaking research that fuels MD Anderson’s mission to end cancer.

spr.ly

2 3

Reposted by Jason M. Schenkel

Aria Vaishnavi, PhD @drariav.bsky.social · May 9

I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer.

www.biorxiv.org/content/10.1...

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling

Secretion of ligands of the human epidermal growth factor (EGFR) family of receptors or erythroblastic leukemia viral oncogene family (ERBB1-4) is a feature common to many cancer cells. However, our u...

www.biorxiv.org

1 6 14

Reposted by Jason M. Schenkel

Center for Immunology-UMN @cfi-umn.bsky.social · Apr 2

Kicking off our journey on BlueSky! We're excited to share updates and connect with you. Follow us and help us get the word out! For more information about the Center for Immunology, go to our website: immunology.umn.edu

Center for Immunology

immunology.umn.edu

1 8 18

Reposted by Jason M. Schenkel

Rachel Rutishauser @rrutishauser.bsky.social · Mar 20

Excited to share this preprint: In trial led by @michaelpelusomd.bsky.social and Steve Deeks, combination immunotherapy=>high rate of HIV control (low VL) after ART pause. @demisandel.bsky.social in our lab found control associated with robust CD8+ T cell proliferation early in response to rebound.

5 11

Reposted by Jason M. Schenkel

Waggoner Lab @labwaggoner.bsky.social · Mar 13

Different injection routes and fluorophores affect anti-CD45.2 antibody leukocyte labeling @jmschenkel.bsky.social @jimmunol.bsky.social @thenatcat.bsky.social
doi.org/10.1093/jimm...

1 4

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

I am very grateful for the team we have and look forward to getting the next few of these out the door! We are not done yet! Though it may be a hot minute before the next one comes out. Hopefully pre-prints soon at least! Stay tuned! 11/end

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

We believe these data will be food for thought for folks interested in using our in vivo labeling. And maybe just a fun read for folks who are lymphatic drainage enthusiasts. Big congrats to the lab for closing out our second paper! 10/n

1 1 1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

In short, BB700 was the big winner. It continuously labeled for over 6 hours in vivo (crazy right???). Applying it to a transplantable tumor model, we found we could identify roughly 7-fold more tumor specific CD8s that had recently migrated compared to IV administration. 9/n

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

Because antibody could be found in the plasma for a while, we speculated we could try and find fluorophores that were capable of labeling at low concentrations. This may provide an opportunity to extend the labeling window for rare events! So that’s what we did with serial dilution experiments. 8/n

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

We next developed a homegrown ELISA to quantify circulating CD45.2 IV and IP antibodies. We saw that IP anti-CD45.2 concentration gradually increased over an hour, while IV disappeared. 7/n

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

Moreover, when we examined leukocyte labeling in blood contiguous compartments like the red pulp of the spleen, liver, and bone marrow, we found that IP antibody labeling intensity increased over the course of an hour, suggesting that labeling was continuously happening. 6/n

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

We find that IP injection of anti-CD45.2 antibody does not label cells in the blood as quickly as an IV injection (duh, I know! But still!). IV injection labels all circulating cells within a minute. Whereas we do not get full labeling by IP injection for at least 10 minutes. 5/n

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

There are a good number of studies looking at this, dating way back to the 40s and 50s. This one from the 80s is particularly well done in my opinion (academic.oup.com/jnci/article...). Don’t feel like reading? IP and IV are different! 4/n

Biodistribution of Antibodies After Intraperitoneal or Intravenous Injection and Effect of Carbohydrate Modifications2

Abstract. These studies were designed to improve the strategy for intraperitoneal immunotherapy of human ovarian carcinoma with monoclonal antibodies (MAbs

academic.oup.com

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

Have you ever wondered about how injecting antibodies via intravenous (IV) or intraperitoneal (IP) injection differs? As a field, we often use IP injection for antibody treatments, and I have always found this to be interesting to think through how IP vs IV injectioun routes may be different. 3/n

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

One of our big limitations was that it was hard to track rare migration events due to a limited labeling window. More on that in a second. 2/n

1

Jason M. Schenkel @jmschenkel.bsky.social · Mar 10

I am pleased to announce that our newest story is officially out at @jimmunol.bsky.social ! academic.oup.com/jimmunol/adv...
This is an immediate follow up to the lab’s first paper from last year. We again thank @jimmunol.bsky.social for a smooth, efficient, and wonderfully fair review process. 1/n

1 2 6

Reposted by Jason M. Schenkel

Wen Jiang MD, PhD @wenjiang-nano.bsky.social · Feb 25

Our newest article is online @naturecancer.bsky.social A new antibody drug conjugate that doesn’t kill tumor cells but rely on immune system to eradicate cancer. @bettykimmdphd.bsky.social @mdanderson.bsky.social

An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy

Nature Cancer - Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.

www.nature.com

2 9

Jason M. Schenkel @jmschenkel.bsky.social · Feb 19

Dorian McGavern at NIH had a paper last year using them - www.nature.com/articles/s41...

Venous-plexus-associated lymphoid hubs support meningeal humoral immunity - Nature

Dural-associated lymphoid tissues are lymphoid structures around vascular hubs in the dura mater that sample antigens and rapidly support humoral immune responses after local ...

www.nature.com

1

Reposted by Jason M. Schenkel

Mark Kaplan @statfourwork.bsky.social · Jan 24

My last editorial in @ImmunoHorizons the little @immunologyaai.bsky.social journal that could. In this commentary I discuss some of the challenges facing academia.

academic.oup.com/immunohorizo...

Give the grant-writing monkeys another banana

You’re probably familiar with the concept that if you had a million monkeys typing on a million computers for a million years, you would eventually get Sha

academic.oup.com

3 9

Reposted by Jason M. Schenkel

Vineet Joag @vjoag.bsky.social · Jan 22

Super excited to announce that the Joag Lab will officially open at @UW, @SCRI in March 2025! We will study the interplay between memory T cells and stromal, humoral, and innate immunity in mucosal tissues. researcherprofiles.seattlechildrens.org/Vineet.Joag. Hiring a technician and a postdoc!

Building Cure at the Seattle Children's Research Institute

2 9 15

Jason M. Schenkel @jmschenkel.bsky.social · Dec 22

Keep your eyes peeled for #2 (jimmunol.bsky.social). And submitted our first big kid grants. Hoping for some kindness from reviewers... Very excited to see what things will look like in another year! What a whirlwind of a job - 2 years have flown by! Feeling both lucky and privileged.

The Journal of Immunology (@jimmunol.bsky.social)

jimmunol.bsky.social

1 2

Jason M. Schenkel @jmschenkel.bsky.social · Dec 22

39 rotations around the sun! And what a year it's been. The lab has doubled in size. We had our first (3!!!) graduate students and post docs join the lab. We had both our first and second lab papers EVER accepted - the first is out in print... so check it out -(journals.aai.org/jimmunol/art...).

Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer

Key Points. IV anti-CD45.2 label lasts for 3 days and tracks leukocyte migration to tissue.There is continuous innate and adaptive leukocyte migration in a

journals.aai.org

1 2 12